首页> 外文期刊>Current Protein and Peptide Science >Biomarkers for Early Diagnosis of Acute Kidney Injury: Current Progress and Clinical Prospects
【24h】

Biomarkers for Early Diagnosis of Acute Kidney Injury: Current Progress and Clinical Prospects

机译:用于早期诊断急性肾损伤的生物标志物:目前的进展和临床前景

获取原文
获取原文并翻译 | 示例
       

摘要

Acute kidney injury (AKI) is one of the most common complications in critically ill patients, resulting in high morbidity and mortality. AKI usually occurs after major surgery, severe infection or drug-induced nephrotoxicity and is associated with prolonged hospital stays, increasedcosts and adverse clinical outcomes. The diagnosis of AKI is currently based on decreased glomerular filtration rate (GFR) and urine output, and increased serum creatinine. Novel biomarkers are required for early identification of patients with AKI to allow timely therapy and improve patientoutcomes. With the advent of proteomics and genomics techniques, a vast array of biomarkers are now available in clinical practice.
机译:急性肾脏损伤(AKI)是危重患者中最常见的并发症之一,导致发病率高和死亡率。 AKI通常发生在主要手术,严重感染或药物诱导的肾毒性之后发生,并且与长期医院住宿,增加和不良临床结果相关。 AKI的诊断目前基于降低的肾小球过滤速率(GFR)和尿量,以及增加的血清肌酐。 需要进行新的生物标志物,以便早期鉴定AKI患者,以便及时治疗和改善患者途径。 随着蛋白质组学和基因组学技术的出现,现在可以在临床实践中获得大量的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号